Acadia Pharmaceuticals (ACAD) PT Raised to $30 at Morgan Stanley
Tweet
Share
E-mailGet Alerts ACAD Hot Sheet
Price: $21.43 +2.58%
Rating Summary:
17 Buy, 10 Hold, 2 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 7 | Down: 20 | New: 25
Rating Summary:
17 Buy, 10 Hold, 2 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 7 | Down: 20 | New: 25
Join SI Premium – FREE
Morgan Stanley analyst Jeffrey Hung raised the price target on Acadia Pharmaceuticals (NASDAQ: ACAD) to $30.00 (from $21.00) while maintaining a Equalweight rating.
You May Also Be Interested In
- Goldman Sachs Upgrades Plains GP Holdings, L.P (PAGP) to Neutral
- Citi Downgrades Ecopetrol SA (EC) to Neutral
- Abivax (ABVX) PT Lowered to $136 at Wolfe Research
Create E-mail Alert Related Categories
Analyst PT ChangeSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
